David A. Siegel Freeline Therapeutics Holdings PLC Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.69 - $1.12 $8,072 - $13,104
-11,700 Reduced 48.95%
12,200 $11,000
Q1 2022

May 16, 2022
BUY
$0.92 - $2.03 $21,988 - $48,516
23,900 New
23,900 $27,000

Others Institutions Holding FRLN

# of Institutions
1
Shares Held
30.1K
Call Options Held
0
Put Options Held
0
View Full List

About Freeline Therapeutics Holdings plc

FRLN Quotes by TradingView
  • Ticker FRLN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,972,300
  • Description
  • Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...
More about FRLN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email